Screener
ARS Pharmaceuticals, Inc. SPRY EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026. Open the filing →
- Filed
- May 15, 2026, 6:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-225142
FAQ
- What is ARS Pharmaceuticals, Inc.'s EBITDA margin?
- ARS Pharmaceuticals, Inc. (SPRY) reported EBITDA margin of -203% in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s EBITDA margin changed year-over-year?
- ARS Pharmaceuticals, Inc.'s EBITDA margin decreased by 174.4% year-over-year, from -74% to -203%.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s EBITDA margin?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s EBITDA margin has grown at a -57.0% compound annual growth rate (CAGR), from -2,664.9% to -211.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about ARS Pharmaceuticals, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude